Jorge Romaguera

6PUBLICATIONS
6CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 02, 2019
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.

Tamer Khashab, Fredrick Hagemeister, Jorge E Romaguera

|Sep 04, 2018
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.

Preetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang

|May 23, 2018
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).

Preetesh Jain, Jorge Romaguera, Samer A Srour

|May 04, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

Jorge E Romaguera, Michael Wang, Lei Feng

Pageof 1

Frequent Collaborators

2 joint publications

Hun J Lee

2 joint publications

Preetesh Jain

1 joint publications

Michael Wang

1 joint publications

Hagop M Kantarjian